PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair
/0 Comments/in Review/by MaxRadiotherapy in High-Burden Hormone-Sensitive Metastatic Prostate Cancer: Can It Be Useful?
/0 Comments/in Review/by MaxTags
abiraterone acetate ADT ai in healthcare alphafold AMG 509 androgen deprivation therapy antibody-drug conjugate apalutamide ARANOTE ATM bispecific antibody bone metastases BRCA2 cancer immunotherapy cancer treatment castration-resistant prostate cancer chemotherapy clinical trial clinical trials crispr darolutamide docetaxel drug discovery drug repurposing drug resistance enzalutamide hormone therapy immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC neuroendocrine prostate cancer oncology oncolytic virus PARP inhibitor personalized medicine preclinical prostate cancer PSMA radioligand therapy radiopharmaceuticals STEAP1 T-cell therapy theranostics
Latest Posts
- Repurposing Antipsychotic Drugs: Potential New Cancer Treatments January 22, 2025
- We can’t always win: LAVA-1207 Development Discontinued, Not Related to Safety Issues January 21, 2025
- Newsletter 3/2025 January 19, 2025
- PARP Inhibitors in Prostate Cancer: Navigating the Complexities of DNA Repair January 18, 2025